4 transcripts
REGN
Earnings call transcript
NASDAQ
2024 Q2
1 Aug 24
the August 22 PDUFA date. The FDA has not informed us of any approvability issues for linvoseltamab related to safety, efficacy or the status of our
REGN
Earnings call transcript
NASDAQ
2024 Q1
2 May 24
independent cohorts from our first-in-human study with a safety profile that is similar to that seen with anti-PD-1 monotherapy with longer-term
REGN
Earnings call transcript
NASDAQ
2023 Q4
2 Feb 24
examples of a checkpoint inhibitor combination with clinically meaningful benefit and with the safety profile that is similar to that seen with anti-PD
REGN
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
clinical efficacy, safety profile, trial design, labeling or drug substance manufacturing nor has the FDA requested any additional clinical data.
The CRL
- Prev
- 1
- Next